Chronic Renal Failure, Anemia, and Parenteral Iron Treatment: From Bench to Bedside

Özet

Anemia is one of the common chronic renal failure (CRF) complications. Reduced renal erythropoietin (EPO) productionand a shortened life span of erythrocytes due to uremic environment and iron deficiency are the main causes of anemia inpatients with CRF. Correcting of iron deficiency constitutes the basis for the treatment of anemia in patients with CRF. Ironreplacement can be done orally or intravenously. The seriousness of anemia and iron deficiency, tolerance of tablet use, response to previous treatments, and the presence of a ready vascular access determine the manner in which iron treatmentis done. New generation parenteral iron preparations have complex carbohydrate structures that strongly bind to iron andreduce plasma free iron release. New generation iron molecules correct iron deficiency without causing an inflammatoryprocess. The point that should be kept in mind is that new formulations may have a side effect profile that has not yet beenexperienced, in addition to various advantages. When using new iron molecules, precaution measures should be takenwith regard to the development of arrhythmia, unstable angina, and hypophosphatemia.